{"id":3158,"date":"2026-08-21T15:40:25","date_gmt":"2026-08-21T08:40:25","guid":{"rendered":"https:\/\/naviva.com.vn\/?p=3158"},"modified":"2026-08-21T15:46:46","modified_gmt":"2026-08-21T08:46:46","slug":"barycela-antibiotic-free-varicella-vaccine-a-new-advancement-in-varicella-prevention","status":"publish","type":"post","link":"https:\/\/naviva.com.vn\/en\/barycela-antibiotic-free-varicella-vaccine-a-new-advancement-in-varicella-prevention","title":{"rendered":"BARYCELA ANTIBIOTIC-FREE VARICELLA VACCINE: A NEW ADVANCEMENT IN VARICELLA PREVENTION"},"content":{"rendered":"

Varicella is an acute infectious disease caused by the Varicella-zoster virus<\/strong>. Although most cases have a mild course, the disease can still lead to serious complications such as skin and soft tissue infections, pneumonia, encephalitis, or sepsis, particularly in young children and individuals at higher risk.[1]<\/span><\/p>\n

With the advancement of science, vaccine manufacturing technologies are continuously being improved to enhance product quality and minimize unnecessary components. Barycela \u2013 a second-generation, antibiotic-free varicella vaccine<\/strong> \u2013 is one of the products developed in line with this approach.<\/span><\/p>\n

1. What is an antibiotic-free varicella vaccine?<\/strong><\/span><\/p>\n

During the manufacturing process of some vaccines, antibiotics may be used to help control the risk of bacterial contamination.<\/span><\/p>\n

Any residual antibiotics in the finished product, if present, must be controlled within the permitted limits in accordance with applicable regulations.<\/span><\/p>\n

An antibiotic-free varicella vaccine<\/strong> is a vaccine manufactured without the use of antibiotics throughout the production process. Removing this component may help minimize the risk of antibiotic-related hypersensitivity associated with residual antibiotics, while also aligning with the development of modern vaccine manufacturing processes.<\/span><\/p>\n

Barycela<\/strong>, developed by GC Biopharma<\/strong>, is based on more than 30 years of research and experience in manufacturing varicella vaccines using the MAV\/06 strain<\/strong>. The vaccine is produced using the MRC-5 human diploid cell line<\/strong>, applying a closed aseptic manufacturing process and single-use technology<\/strong> in accordance with GMP standards. This enables strict control throughout the manufacturing process without the need for antibiotics.[2]<\/span><\/p>\n

2. Safety and efficacy standards meeting WHO requirements<\/strong><\/span><\/p>\n

Barycela has been included by the World Health Organization (WHO)<\/strong> in the list of vaccines that have received WHO Prequalification<\/strong>, effective from February 14, 2023.[3] This process involves assessment based on standards for quality, safety, efficacy, and the ability to meet requirements for use in immunization programs.<\/span><\/p>\n

Some key features of Barycela include:<\/span><\/p>\n